首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 156 毫秒
1.
花生四烯乙醇胺(arachidonoylethanolamide,anandamide,ANA)是近年来确定的大麻素受体的内源性配基,它主要分布在中枢神经系统、免疫系统及子宫等部位,具有大麻的主要活性成分--Δ9-四氢大麻酚(Δ9-THC)的药理功能.ANA有两种受体,即脑型受体(CB1)和脾型受体(CB2),它们都是与GTP偶联的跨膜受体,是ANA发挥作用的主要途径.脂肪酸酰胺水解酶(fattyacidamidehydrolase,FAAH)是ANA特异性极高的水解酶,它可以迅速调节ANA在体内的含量,从而发挥特异的生理作用.  相似文献   

2.
唐正露  韩敏敏  曹堃  李亮  李郁 《微生物学通报》2021,48(11):4209-4220
[背景] 相较于灭活疫苗和弱毒疫苗,沙门氏菌(Salmonella)基因工程减毒活疫苗具有的优越性逐渐显现,研究也不断深入。[目的] 探究肠炎沙门氏菌G9菌株的4株基因缺失株G9(ΔhilA)、G9(ΔhilD)、G9(ΔssrABhilA)和G9(ΔssrABhilAhilD)的免疫效果及生物安全性。[方法] 以肠炎沙门氏菌基因缺失菌株G9(ΔhilA)、G9(ΔhilD)、G9(ΔssrABhilA)、G9(ΔssrABhilAhilD)及其亲本菌株G9的最佳免疫剂量接种小鼠后,利用间接ELISA法、流式细胞术、MTT法、小鼠攻毒试验及倾注平板法等对各缺失株的免疫效果和安全性进行评价。[结果] G9(ΔhilD)诱导血清IgG抗体效价最高,G9(ΔhilD)和G9(ΔssrABhilAhilD)产生肠黏膜IgA抗体效价最高,4株缺失菌诱导IL-4、IL-10、IFN-γ、TNF-β、MCP-1细胞因子的能力与亲本株G9差异不显著(P>0.05),产生的CD4+/CD3+、CD8+/CD3+ T细胞比率呈上升趋势,而且G9(ΔssrABhilA)和G9(ΔssrABhilAhilD)最高;G9(ΔssrABhilAhilD)诱发的脾淋巴细胞增殖指数最高;免疫小鼠后4株缺失株对G9攻毒提供的保护率为80%-100%,而且小鼠肝脏、脾脏及小肠绒毛无明显病理变化,对鼠伤寒沙门氏菌攻毒提供的保护率为50%-80%;接种后12 d,小鼠肝脏、脾脏及小肠中定殖的菌株能基本清除,而且在体外能连续稳定传代30代。[结论] G9(ΔhilA)、G9(ΔhilD)、G9(ΔssrABhilA)和G9(ΔssrABhilAhilD)对小鼠的免疫效果和生物安全性均良好,有成为肠炎沙门氏菌基因工程减毒活疫苗的可能。  相似文献   

3.
邹冈 《生命科学》1997,9(5):197-199
大麻是当前西方社会服用人数最多的滥用药,其有效成分为△~9-四氢大麻醇。由于脂溶性高,以往认为其作用系改变神经细胞膜磷脂双层的物化性质。后来找到了一些(人工)合成(的)化合物作用更强,但水溶性增加;用它们作为配体证明有受体存在,并已克隆。CB1受体在脑组织,CB2受体在免疫组织,均系G-蛋白偶合型。根据药物→受体→内源性配体的规律,又找到了大麻受体的内源性配体花生四烯酸乙醇胺。至此证明体内存在着内源性大麻系统,使该领域的研究迈进到一崭新的时期。  相似文献   

4.
中华绒螯蟹眼柄MTXO细胞GABA受体通道研究   总被引:3,自引:0,他引:3  
采用全细胞膜片钳技术测定了中华绒螯蟹(Eriocheir sinensis)眼柄视神经节端髓X器官(MTXO)三种类型神经内分泌细胞对0.01~5mmol/L γ氨基丁酸(γ-aminobutyric acid,GABA)的反应,并结合选择性拮抗剂和激动剂的使用进行了GABA受体研究.在电流钳模式下,依据不同Nernst Cl电位,三种类型细胞均对GABA产生去极化或超级化反应.在电压钳模式下,GABA激活Cl通道电流(IGABA).IGABA在灌流GABA后约1 200 ms内激活,800 ms内达到峰值,没有明显的脱敏反应,反转电位接近Nernst Cl电位.IGABA幅值呈浓度依赖性,激活阈值为0.01 mmol/L,约在0.5 mmol/L达到饱和.药理学实验结果表明,中华绒螯蟹眼柄神经内分泌细胞GABA受体是Cl通道蛋白,对Cl离子通道阻断剂Picrotoxin和Niflumic acid敏感,但是对GABAA受体拮抗剂Bicuculline和GABAC受体激动剂cis-4-aminocrotonic acid (CACA)和trans-4-aminocrotonic (TACA)均不敏感.  相似文献   

5.
维生素D(VD)为固醇类衍生物,除发挥抗佝偻病作用,还具有一定的免疫调节功能。主要研究VD对实验性脑疟小鼠树突状细胞的影响。结果显示,与对照组相比,在伯氏疟原虫(P.bANKA)感染前给予VD,可降低C57BL/6小鼠发生脑型疟疾的风险,存活时间明显延长。VD预处理后,脾脏中髓样树突状细胞(CD11c+CD11b+)和浆样树突状细胞(CD11c+B220+)百分率明显降低,CD11c+MHCII+细胞、CD11c+TLR4+细胞和CD11c+TLR9+细胞的百分含量也显著减少。由此提示,预防性口服VD可抑制感染小鼠树突状细胞的数量和功能,对脑型疟疾的发生具有一定预防作用,为新型抗疟药物的研发提供参考。  相似文献   

6.
二氢嘧啶脱氢酶基因(DPYD基因)所编码的二氢嘧啶脱氢酶(DPD酶)是氟化嘧啶类抗肿瘤药物代谢的主要限速酶,其活性存在显著的个体差异,并因此影响药物的疗效和毒副作用.大部分编码低/无活性酶的突变型等位基因是由于基因中的单核苷酸多态性(single nucleotide polymorphism,SNP)造成的,检测这些SNPs是预测患者对药物的反应和实现个体化给药方案的基础.制备并优化了用于检测DPYD基因中6个已知SNPs所编码的等位基因(DPYD*2,*3,*4,*5,*9,*12)的基因芯片,建立了该芯片的基因分型标准.并利用该芯片检测了肿瘤患者(112例)、肾病患者(83例)和健康者(45例)中DPYD突变型等位基因的发生频率.在受试人群中,突变型等位基因DPYD*5和DPYD*9平均发生率分别为32.08%和11.25%,未发现DPYD*2,*3,*4,*12突变型等位基因.而且以上单碱基突变的发生率在肿瘤患者、肾病患者和健康者间以及男性、女性肿瘤患者间无显著性差异,表明其与疾病的发生或性别无显著性关联.对20例标本的基因分型结果采用直接测序法进行验证,19例基因芯片分型结果与直接测序法结果相一致.DPYD*5、DPYD*9突变型等位基因在受试人群中具有较高的发生率.利用基因芯片能够对其实现快速准确的检测.  相似文献   

7.
蛋白质感染颗粒(PrP)的错误折叠被认为是引起一些神经退化性疾病的主因,但其正常构象(PrPC)的功能却一直不为人所知.近年来研究发现,在正常细胞中,尤其是脑细胞中,细胞膜PrPC可通过内吞作用进入细胞质而将Cu2+载运至SOD1,从而参与调节SOD1 的活性及细胞铜代谢.另有研究表明,Cu2+对于PrPSc(错误构象)的蛋白水解酶K抗性的恢复及不同“病株”的形成也有很重要的作用.  相似文献   

8.
缓激肽是一含有9个氨基酸残基的多肽,其残基序列为Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9-OH,在激肽释放酶的作用下, 从其大的前体多肽——激肽原而形成的.许多发病机理,如发炎、疼痛、哮喘等都与缓激肽有关. 它能与PC12细胞表面的受体作用,引起细胞器内的钙离子释放,在共焦显微镜下,通过观察钙指示剂Fluo-3荧光增加来监测缓激肽的生物活性.在这项研究中,利用固相肽合成方法合成了连接生物素的缓激肽,Biotin-Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9-OH,通过对其生物活性的研究发现:a.它能保持象天然的缓激肽那样的生物活性;b.由于中性抗生物素蛋白与连接的生物素的结合引起的空间位阻阻碍它与细胞表面受体的相互作用,从而抑制了它的生物活性;c.在有自由的生物素存在的条件下,自由生物素与连接生物素与中性抗生物素蛋白的竞争结合,能够使得与中性抗生物素蛋白结合的连接生物素的缓激肽从抗生物素蛋白上脱离,因而恢复其生物活性.因此,可利用生物素和抗生物素蛋白来控制连接生物素的缓激肽的生物活性.这对于研究生物体系中生物活性的结构相关性具有重要的意义.  相似文献   

9.
同源重组法构建多功能农药降解基因工程菌研究   总被引:13,自引:1,他引:12  
构建遗传稳定的多功能农药降解基因工程菌可以为农药污染的生物修复提供良好的菌种资源,然而,构建遗传稳定且不带入外源抗性的基因工程菌是一个难点。通过以受体菌的16S rDNA为同源重组指导序列、sacB基因为双交换正筛选标记构建同源重组载体,二亲结合的方法将甲基对硫磷水解酶基因(mpd)整合到呋喃丹降解菌Sphingomonas sp.CDS1染色体的16S rDNA位点,分别成功构建了含1个和2个mpd基因插入到rDNA位点且不带入外源抗性的基因工程菌株CDSmpd和CDS-2mpd。同源重组单交换的效率为3.7×10-7~6.8×10-7。通过PCR和Southern杂交的方法验证了同源重组事件。基因工程菌遗传稳定,能同时降解甲基对硫磷和呋喃丹。甲基对硫磷水解酶(MPH)的比活在各生长时期均高于原始出发菌株,比活最高达6.22 mu/μg。  相似文献   

10.
为了研究胶质细胞源性神经营养因子 (GDNF) 在中枢神经系统疾病中的治疗应用,运用基因突变、蛋白质融合表达和蛋白质纯化技术获得分子质量较小的GDNF(ΔN39)活性片段. 将HIV-1 Tat 蛋白转导区 (protein transduction domain,PTD) 的9个碱性氨基酸49RKKRRQRRR57模拟物9个精氨酸(R9)与GDNF(ΔN39)活性片段融合表达,获得纯度达95%以上的GDNF(ΔN39)-R9融合蛋白. 将GDNF、GDNF(ΔN39)、GDNF(ΔN39)-R9分别加入原代培养的中脑多巴胺能神经元和转染GDNF受体GFRα1和Ret的PC12细胞中,观察它们的神经营养活性和毒性. 运用脑微血管内皮细胞株B-Endo 3,观察GDNF(ΔN39)-R9蛋白穿越血管内皮细胞膜的功能;运用脑血管内皮细胞和Matrigel铺板模拟血脑屏障,Transwell法检测Tat-GDNF(ΔN39)蛋白穿越脑血管内皮细胞和外周胶质膜的能力. 结果显示:GDNF(ΔN39)-R9蛋白具有类似GDNF的神经营养活性,促进原代培养的中脑多巴胺能神经元和稳定表达GFRα1和Ret受体的PC12-GFRα1-Ret细胞株的存活,没有显示毒性,并且能很好地穿过脑微血管内皮细胞层和模拟的血脑屏障.  相似文献   

11.
Effects of anandamide on embryo implantation in the mouse   总被引:4,自引:0,他引:4  
Liu WM  Duan EK  Cao YJ 《Life sciences》2002,71(14):1623-1632
Anandamide (N-arachidonoylethanolamine), an arachidonic acid derivative, is an endogenous ligand for both the brain-type (CB1-R) and spleen-type (CB2-R) cannabinoid receptors. To investigate the possible effects of anandamide on embryo implantation in the mouse, we used a co-culture system in which mouse embryos are cultured with a monolayer of uterine epithelial cells. Our results indicate that 14 nM anandamide significantly promotes the attachment and outgrowth of the blastocysts on the monolayer of uterine epithelial cells, and those effects could be blocked by CB1-R antagonists SR141716A, but not by SR144528, a CB2-R antagonist. It suggests that the effects of anandamide on embryo attachment and outgrowth are mediated by CB1-R. However, 56 nM anandamide is capable of inhibiting the blastocyst attachment and outgrowth, we, therefore, conclude that anandamide may play an essential role at the outset of implantation.  相似文献   

12.
The pharmacological profiles of the endocannabinoid anandamide and exogenous cannabinoids (e.g., Delta9-tetrahydrocannabinol) are similar, but not exactly the same. One notable difference is that anandamide's in vivo effects in mice are not blocked by the brain cannabinoid (CB1) receptor antagonist SR141716A. The degree to which the rapid metabolism of anandamide to arachidonic acid might be involved in this unexpected lack of effect was the focus of this study. Mice were tested in a tetrad of tests sensitive to cannabinoids, consisting of spontaneous locomotion, ring immobility, rectal temperature and tail flick nociception. Anandamide and arachidonic acid produced a similar profile of effects, but neither drug was blocked by SR141716A. When hydrolysis of anandamide was inhibited by an amidase inhibitor (phenylmethyl sulfonyl fluoride; PMSF), however, SR141716A significantly attenuated anandamide's effects but did not completely block them. Similarly, the effects of the metabolically stable anandamide analog O-1812 were attenuated by SR141716A. The role of oxidative metabolism in anandamide's effects in the tetrad was also investigated through pharmacological modulation of cyclooxygenase and lipoxygenase, two major classes of enzymes that degrade arachidonic acid. Whereas the non-selective cyclooxygenase inhibitor ibuprofen blocked the in vivo effects of arachidonic acid, it did not alter anandamide's effects. Other modulators of the cyclooxygenase and lipoxygenase pathways also failed to block anandamide's effects. Together, these results offer partial support for a pharmacokinetic explanation of the failure of SR141716A to antagonize the effects of anandamide; however, they also suggest that non-CB1, non-CB2 receptors may be involved in mediation of anandamide's in vivo actions, particularly at higher doses.  相似文献   

13.
The major psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, affects emotional states in humans and laboratory animals by activating brain cannabinoid receptors. A primary endogenous ligand of these receptors is anandamide, the amide of arachidonic acid with ethanolamine. Anandamide is released in selected regions of the brain and is deactivated through a two-step process consisting of transport into cells followed by intracellular hydrolysis. Pharmacological blockade of the enzyme fatty acid amide hydrolase (FAAH), which is responsible for intracellular anandamide degradation, produces anxiolytic-like effects in rats without causing the wide spectrum of behavioral responses typical of direct-acting cannabinoid agonists. These findings suggest that anandamide contributes to the regulation of emotion and anxiety, and that FAAH might be the target for a novel class of anxiolytic drugs.  相似文献   

14.
N -arachidonoylethanolamine (anandamide) was the first endogenous cannabinoid receptor ligand to be discovered. Dual synthetic pathways for anandamide have been proposed. One is the formation from free arachidonic acid and ethanolamine, and the other is the formation from N -arachidonoyl phosphatidylethanolamine (PE) through the action of a phosphodiesterase. These pathways, however, do not appear to be able to generate a large amount of anandamide, at least under physiological conditions. The generation of anandamide from free arachidonic acid and ethanolamine is catalyzed by a degrading enzyme anandamide amidohydrolase/fatty acid amide hydrolase operating in reverse and requires large amounts of substrates. As for the second pathway, arachidonic acids esterified at the 1-position of glycerophospholipids, which are mostly esterified at the 2-position, are utilized for the formation of N -arachidonoyl PE, a stored precursor form of anandamide. In fact, the actual levels of anandamide in various tissues are generally low except in a few cases. 2-Arachidonoylglycerol (2-AG) was the second endogenous cannabinoid receptor ligand to be discovered. 2-AG is a degradation product of arachidonic acid-containing glycerophospholipids such as inositol phospholipids. Several investigators have demonstrated that 2-AG is produced in a variety of tissues and cells upon stimulation. 2-AG acts as a full agonist at the cannabinoid receptors (CB1 and CB2). Evidence is gradually accumulating and indicates that 2-AG is the most efficacious endogenous natural ligand for the cannabinoid receptors.In this review, we summarize the tissue levels, biosynthesis, degradation and possible physiological significance of two endogenous cannabimimetic molecules, anandamide and 2-AG.  相似文献   

15.
Several cannabinoids elicit systemic vasodilation, mainly via CB1 cannabinoid and vanilloid receptors. However, effects in the pulmonary circulation are unknown. Using the isolated, ventilated, buffer-perfused rabbit lung, we have shown that the endocannabinoids arachidonyl ethanolamide (anandamide) and 2-arachidonyl glycerol (2-AG) dose-dependently increase pulmonary arterial pressure (+19.9 +/- 3.4 mmHg, 5 microM, and +39.5 +/- 10.8 mmHg, 0.4 microM, respectively). 2-AG induced lung edema. The CB1 receptor antagonist AM-251 (0.1 and 5 microM) and the VR1 vanilloid receptor antagonist capsazepine (10 microM) failed to reduce anandamide's effects. The metabolically stable anandamide and 2-AG analogs R-methanandamide and noladin ether, Delta9-tetrahydrocannabinol, and the synthetic cannabinoid HU-210, which is no arachidonic acid product, were without effect. The unspecific cyclooxygenase (COX) inhibitor aspirin (100 microM, P < 0.001) and the specific COX-2 inhibitor nimesulide (10 microM, P < 0.01) completely prevented pulmonary hypertension after 5 microM anandamide. COX-2 RNA was detected in rabbit lungs. The synthetic thromboxane receptor antagonist SQ 29,548 was without effect, but the specific EP1 prostanoid receptor antagonist SC-19220 (100 microM) inhibited the pressure increase after anandamide (P < 0.05). PCR analysis detected fatty acid amidohydrolase (FAAH), an enzyme that degrades endocannabinoids, in rabbit lung tissue. Furthermore, the specific FAAH inhibitor methyl arachidonyl fluorophosphonate (0.1 microM) blocked pressure effects of anandamide (P < 0.01). Finally, anandamide (99 +/- 55 pmol/g) and 2-AG (19.6 +/- 8.4 nmol/g) were found in native lungs. We conclude that anandamide increases pulmonary arterial pressure via COX-2 metabolites following enzymatic degradation by FAAH into arachidonic acid products.  相似文献   

16.
Anandamide, an endogenous ligand for cannabinoid receptors, loses its biological activities when it is hydrolyzed to arachidonic acid and ethanolamine by anandamide amidohydrolase. We overexpressed a recombinant rat enzyme with a hexahistidine tag in a baculovirus-insect cell expression system, and purified the enzyme with the aid of a Ni-charged resin to a specific activity as high as 5.7 micromol/min/mg protein. The purified recombinant enzyme catalyzed not only the hydrolysis of anandamide and palmitoylethanolamide, but also their reverse synthetic reactions. In order to attain an equilibrium of the anandamide hydrolysis and its reverse reaction within 10 min, we utilized a large amount of the purified enzyme. The equilibrium constant ([arachidonic acid][ethanolamine])/([anandamide][water]) was calculated as 4x10(-3) (37 degrees C, pH 9.0). These experimental results with a purified enzyme preparation quantitatively confirmed the reversibility of the enzyme reaction previously observed with crude enzyme preparations.  相似文献   

17.
Anandamide (N-arachidonoylethanolamine), an arachidonic acid derivative, is an endogenous ligand for both the brain-type (CB1-R) and spleen-type (CB2-R) cannabinoid receptors. We have previously demonstrated that preimplantation mouse embryos express mRNA for these receptors and that the periimplantation uterus contains the highest level of anandamide yet discovered in a mammalian tissue. We further demonstrated that 2-cell mouse embryos exposed to low levels of anandamide (7 nM) or other known cannabinoid agonists in culture exhibit markedly compromised embryonic development to blastocysts and that this effect is mediated by CB1-R. In contrast, the present study demonstrates that blastocysts exposed in culture to the same low levels of cannabinoid agonists exhibited accelerated trophoblast differentiation with respect to fibronectin-binding activity and trophoblast outgrowth. Again, these effects resulted from activation of embryonic CB1-R. There was a differential concentration-dependent effect of cannabinoids on the trophoblast, with an observed inhibition of differentiation at higher doses. These results provide evidence for the first time that cannabinoid effects are differentially executed depending on the embryonic stage and cannabinoid levels in the environment. Since uterine anandamide levels are lowest at the sites of implantation and highest at the interimplantation sites, the new findings imply that site-specific levels of anandamide and/or other endogenous ligands in the uterus may regulate implantation spatially by promoting trophoblast differentiation at the sites of blastocyst implantation.  相似文献   

18.
The endogenous cannabinoid anandamide produces cannabimimetic effects similar to those produced by delta9-tetrahydrocannabinol (delta9-THC), but has a much shorter duration of action due to its rapid metabolism to arachidonic acid and polar metabolites via action of fatty acid amide hydrolase (FAAH). Our earlier observations that anandamide's effects persisted after brain levels of anandamide itself had substantially dropped prompted us to examine the influence of the irreversible amidase inhibitor, phenylmethyl sulfonyl fluoride (PMSF), on the brain levels and pharmacological effects of anandamide. As shown previously, pretreatment with PMSF resulted in a leftward shift of the anandamide dose effect curves for antinociception and hypothermia in male mice. Brain and plasma levels of anandamide, arachidonic acid and polar metabolites peaked at 1 min after i.v. injection with 3H-anandamide and remained high at 5 min post-injection, with levels falling sharply thereafter. Pretreatment with PMSF (30 mg/kg, i.p.) prior to an injection of 1 or 10 mg/kg 3H-anandamide resulted 5 min later in enhanced brain levels of anandamide compared to those obtained with 3H-anandamide plus vehicle injection. Levels of arachidonic acid and polar metabolites in brain were not significantly increased. The clear correspondence between brain levels of anandamide following pretreatment with PMSF and pharmacological activity suggests that this parent compound is responsible for the antinociception and hypothermia that occurred 5 min after injection. These results further suggest that metabolite contribution to anandamide's effects, if any, would occur primarily at later times.  相似文献   

19.
Anandamide (N-arachidonoylethanolamine, AEA), an endogenous cannabinoid receptor agonist, causes potent vasodilation in the cerebral circulation through an endothelial-dependent or -independent mechanism. We have investigated the processing of [3H]AEA in cultured mouse cerebral microvascular endothelial cells (MEC) in order to better understand its mechanism of action in the cerebral vasculature. These cells took up anandamide very quickly, reaching a maximum value in 5 min and remaining at that level for at least 8 h. Analysis of the cell lipids demonstrated that, in addition to free anandamide, radioactivity was incorporated into phosphatidylcholine (PC), phosphatidylinositol (PI), and phosphatidylethanolamine (PE) in a time-dependent manner. Analysis of the hydrolyzed cell lipids indicated that anandamide was converted to arachidonic acid, a process that was inhibited by the selective fatty acid amide hydrolase inhibitor oleyl trifluoromethyl ketone (OTMK). Phospholipase A2 (PLA2) hydrolysis of the PC, PI, and PE fractions indicated that the arachidonic acid formed from anandamide was esterified predominately into sn-2 position of the endothelial phospholipids. Furthermore, anandamide and arachidonic acid were released when the cells were incubated with A23187. These results suggest that the biological activity of anandamide might be regulated by its rapid uptake and calcium-dependent release in endothelial cells, and conversion of anandamide to arachidonic acid might serve as an inactivation process in the cerebral microcirculation.  相似文献   

20.
The salivary glands and saliva from the lone star tick Amblyomma americanum (L.) were analyzed for the presence of the two endogenous agonists of cannabinoid receptors, N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), as well as of the anandamide congener, N-palmitoylethanolamine (PEA), an anti-inflammatory and analgesic mediator that is inactive at cannabinoid receptors. Two very sensitive mass-spectrometric techniques were used for this purpose. Both 2-AG and PEA, as well as other N-acylethanolamines (NAEs), were identified in salivary glands, but anandamide was below detection. The levels of 2-AG were considerably higher in the salivary glands of partially fed than replete females. Ex vivo gland stimulation with arachidonic acid increased the levels of 2-AG, but not of PEA or other NAEs, and caused the formation of anandamide and of the potent analgesic compound N-arachidonoylglycine. Instead, the amounts of anandamide, 2-AG and PEA were not influenced by treatment of salivary glands with dopamine, which stimulates saliva secretion. The possible biosynthetic precursors of anandamide, PEA and other NAEs were also detected in salivary glands, whereas only PEA was detected in tick saliva. These data demonstrate for the first time that the salivary glands of an obligate ectoparasite species can make endocannabinoids and/or related congeners with analgesic and anti-inflammatory activity, which possibly participate in the inhibition of the host defense reactions.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号